# A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma

> **NCT02358395** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** BBI608
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02358395
- **Lead sponsor:** Sumitomo Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02358395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02358395, "A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02358395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*